HLA-A11.1/B2M(2)

Nomenclature

C57BL/6JSmo-B2mtm1(hB2M-linker-HLA-A*1101/H2-D1)Smoc

Cat. NO.

NM-HU-241354

Strain State

Repository Live

Export PDF

Gene Summary

Gene Symbol
B2M

Model Description

The endogenous mouse B2m gene was replaced by hB2M-linker-HLA-A*1101/H2-D1 gene.

Validation Data

image.png

Fig.1 Expression analysis of hB2M and HLA-ABC on CD45+ cells in blood of HLA-A11.1/B2M humanized mice. 

Leukocytes were collected from wild-type C57BL/6 mice(11 weeks old)  and homozygous HLA-A11.1/B2M humanized mice(15.7 weeks old) , and analyzed by flow cytometry with anti-mB2M, anti-hB2M, anti-mH2D and anti-HLA-ABC. hB2M and HLA-ABC were exclusively detectable in HLA-A11.1/B2M humanized mice, whereas mB2M and mH2D were exclusively detectable in wild-type C57BL/6 mice.

image.png

Fig.2 Analysis of immune cell subpopulations in the blood (n=3 per group). 

Leukocytes were collected from the blood of wild-type C57BL/6 mice (female, 8 weeks old; male, 9 weeks) and homozygous HLA-A11.1/B2M humanized mice (9 weeks old), and Flow cytometry analysis was performed to assess leukocyte subpopulations.

Abbr.  WT, wild type; HO, homozygous.

image.png

Fig.3 Analysis of immune cell subpopulations in the spleen (n=3 per group). 

Leukocytes were collected from the spleens of wild-type C57BL/6 mice (female, 8 weeks old; male, 9 weeks) and homozygous HLA-A11.1/B2M humanized mice (9 weeks old), and flow cytometry analysis was performed to assess leukocyte subpopulations.

Abbr.  WT, wild type; HO, homozygous.
4b83fc87-7c9d-4202-bcb5-9ad7ad49b858.png

Fig.4 Detection of KrasG12V vaccine and peptide induced immune responses in HLA-A11.1/B2M mice by ELISpot assay.

Splenocytes from mice immunized with PBS, or KRAS G12V LNP-mRNA were collected and stimulated in vitro with RPMI 1640 medium(Non-stimulation), NY-ESO-1: 157–165, KRAS G12V: 8–16, or cell stimulation cocktail (PC), respectively. Upon stimulation with KrasG12V: 8-16 peptide, WT mice showed no response, whereas HLA-A11.1/B2M mice after KRAS G12V mRNA-LNP immunization generated a robust cellular immune response.

3ac4bf59-9ba5-421e-9693-50da7f896c22.png

Fig.5 KrasG12V: 8-16 peptide tetramer+ T cells assays.

Splenocytes from mice immunized with PBS or KRAS G12V LNP-mRNA were collected and stimulated with the hHLA-11.1-restricted KRAS G12V: 8–16 peptide. Flow cytometry analysis revealed that the KRAS G12V mRNA-LNP vaccine predominantly elicited a strong antigen-specific CD8+ T cell expansion (~20%).

01d3dd44-d71f-4bfe-9bac-d62931c26f07.png

Fig.6 T-cell intracellular cytokine staining (ICS) assays.

Splenocytes from groups G1–G5 were collected and stimulated with PBS (NC), NY-ESO-1: 157–165, KRAS G12V: 8–16, or cell stimulation cocktail (PC), respectively and analyzed. Flow cytometry analysis revealed that only the hHLA-11.1/B2M mice immunized with KRAS G12V LNP-mRNA (G4) generated a large number of IFN-γ-positive CD4+ and CD8+ T cells.


You may also like

Shanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute

On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.

Learn more

Customizing Mouse Models: Delivering in 100 Days to Speed Up Your Research!

At GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.

Learn more

Milestones

Our vision is to provide researchers all over the world with comprehensive, convenient and professional animal model services to facilitate a simplified and highly-efficient approach towards uncovering the mysteries of life.

Learn more